Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells

Cancer Letters

Volumn 344, Issue 1, 2014, Pages 129-137

  Luo, Xue Gang ^a,b   Zhang, Chun Ling ^a,b   Zhao, Wen Wen ^a,b   Liu, Zhi Peng ^a,b   Liu, Lei ^a,b   Mu, Ai ^a,b   Guo, Shu ^a,b   Wang, Nan ^a,b   Zhou, Hao ^a,b   Zhang, Tong Cun ^a,b,c  

^a TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Tianjin Key Laboratory of Industrial Microbiology   (China)

^c WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Breast cancer; Cell migration; Histone methylation; MRTF A; MYL9; SMYD3; Transactivation

Indexed keywords

HISTONE METHYLTRANSFERASE; MYOCARDIN RELATED TRANSCRIPTION FACTOR A; MYOSIN LIGHT CHAIN; MYOSIN REGULATORY LIGHT CHAIN 9; SET AND MYND DOMAIN CONTAINING PROTEIN 3; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTONE METHYLATION; MRTF A GENE; MYL9 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SMYD3 GENE; TRANSACTIVATION; TRANSCRIPTION REGULATION;

BREAST CANCER; CELL MIGRATION; HISTONE METHYLATION; MRTF-A; MYL9; SMYD3; TRANSACTIVATION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MOVEMENT; DNA-BINDING PROTEINS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MCF-7 CELLS; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84893637263     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.10.026     Document Type: Article

References (36)

1. Vartiainen M.K., Guettler S., Larijani B., Treisman R. Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL. Science 2007, 316:1749-1752.
2. Cen B., Selvaraj A., Burgess R.C., Hitzler J.K., Ma Z., Morris S.W., Prywes R. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes. Molecular and Cellular Biology 2003, 23:6597-6608.
3. Parmacek M.S. Myocardin-related transcription factors: critical coactivators regulating cardiovascular development and adaptation. Circulation Research 2007, 100:633-644.
4. Sun Y., Boyd K., Xu W., Ma J., Jackson C.W., Fu A., Shillingford J.M., Robinson G.W., Hennighausen L., Hitzler J.K., Ma Z., Morris S.W. Acute myeloid leukemia-associated Mkl1 (Mrtf-a) is a key regulator of mammary gland function. Molecular and Cellular Biology 2006, 26:5809-5826.
5. Medjkane S., Perez-Sanchez C., Gaggioli C., Sahai E., Treisman R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nature Cell Biology 2009, 11:257-268.
6. Scharenberg M.A., Chiquet-Ehrismann R., Asparuhova M.B. Megakaryoblastic leukemia protein-1 (MKL1): Increasing evidence for an involvement in cancer progression and metastasis. The International Journal of Biochemistry and Cell Biology 2010, 42:1911-1914.
7. Hamamoto R., Furukawa Y., Morita M., Iimura Y., Silva F.P., Li M., Yagyu R., Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nature Cell Biology 2004, 6:731-740.
8. Zou J.N., Wang S.Z., Yang J.S., Luo X.G., Xie J.H., Xi T. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF. Cancer Letters 2009, 280:78-85.
9. Luo X.G., Ding Y., Zhou Q.F., Ye L., Wang S.Z., Xi T. SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells. Journal of Bioscience and Bioengineering 2007, 103:444-450.
10. Cock-Rada A.M., Medjkane S., Janski N., Yousfi N., Perichon M., Chaussepied M., Chluba J., Langsley G., Weitzman J.B. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Research 2012, 72:810-820.
11. Luo X.G., Zou J.N., Wang S.Z., Zhang T.C., Xi T. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life 2010, 62:194-199.
12. Fujii T., Tsunesumi S., Yamaguchi K., Watanabe S., Furukawa Y. Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish. PloS One 2011, 6:e23491.
13. Callis T.E., Cao D., Wang D.Z. Bone morphogenetic protein signaling modulates myocardin transactivation of cardiac genes. Circulation Research 2005, 97:992-1000.
14. Liu Y., Chen W., Gaudet J., Cheney M.D., Roudaia L., Cierpicki T., Klet R.C., Hartman K., Laue T.M., Speck N.A., Bushweller J.H. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell 2007, 11:483-497.
15. Kim H., Heo K., Kim J.H., Kim K., Choi J., An W. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. The Journal of Biological Chemistry 2009, 284:19867-19877.
16. Rea S., Eisenhaber F., O'Carroll D., Strahl B.D., Sun Z.W., Schmid M., Opravil S., Mechtler K., Ponting C.P., Allis C.D., Jenuwein T. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000, 406:593-599.
17. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
18. Pipes G.C., Creemers E.E., Olson E.N. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes and Development 2006, 20:1545-1556.
19. Milyavsky M., Shats I., Cholostoy A., Brosh R., Buganim Y., Weisz L., Kogan I., Cohen M., Shatz M., Madar S., Kalo E., Goldfinger N., Yuan J., Ron S., MacKenzie K., Eden A., Rotter V. Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer Cell 2007, 11:133-146.
20. Yoshio T., Morita T., Tsujii M., Hayashi N., Sobue K. MRTF-A/B suppress the oncogenic properties of v-ras- and v-src-mediated transformants. Carcinogenesis 2010, 31:1185-1193.
21. Leitner L., Shaposhnikov D., Mengel A., Descot A., Julien S., Hoffmann R., Posern G. MAL/MRTF-A controls migration of non-invasive cells by upregulation of cytoskeleton-associated proteins. Journal of Cell Science 2011, 124:4318-4331.
22. Krendel M., Mooseker M.S. Myosins: tails (and heads) of functional diversity. Physiology 2005, 20:239-251.
23. Licht A.H., Nubel T., Feldner A., Jurisch-Yaksi N., Marcello M., Demicheva E., Hu J.H., Hartenstein B., Augustin H.G., Hecker M., Angel P., Korff T., Schorpp-Kistner M. Junb regulates arterial contraction capacity, cellular contractility, and motility via its target Myl9 in mice. The Journal of Clinical Investigation 2010, 120:2307-2318.
24. Cermak V., Kosla J., Plachy J., Trejbalova K., Hejnar J., Dvorak M. The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells. Cellular and Molecular Life Sciences:CMLS 2010, 67:3557-3568.
25. Ibrahim S.A., Yip G.W., Stock C., Pan J.W., Neubauer C., Poeter M., Pupjalis D., Koo C.Y., Kelsch R., Schule R., Rescher U., Kiesel L., Gotte M. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism, International journal of cancer. Journal International du Cancer 2012, 131:E884-896.
26. Minami T., Kuwahara K., Nakagawa Y., Takaoka M., Kinoshita H., Nakao K., Kuwabara Y., Yamada Y., Yamada C., Shibata J., Usami S., Yasuno S., Nishikimi T., Ueshima K., Sata M., Nakano H., Seno T., Kawahito Y., Sobue K., Kimura A., Nagai R., Nakao K. Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. The EMBO Journal 2012, 31:4428-4440.
27. Liao X.H., Wang N., Liu Q.X., Qin T., Cao B., Cao D.S., Zhang T.C. Myocardin-related transcription factor-A induces cardiomyocyte hypertrophy. IUBMB Life 2011, 63:54-61.
28. Xing W., Zhang T.C., Cao D., Wang Z., Antos C.L., Li S., Wang Y., Olson E.N., Wang D.Z. Myocardin induces cardiomyocyte hypertrophy. Circulation Research 2006, 98:1089-1097.
29. Small E.M., Warkman A.S., Wang D.Z., Sutherland L.B., Olson E.N., Krieg P.A. Myocardin is sufficient and necessary for cardiac gene expression in Xenopus. Development 2005, 132:987-997.
30. Zhou J., Liao X.H., Wu C., Li J., Xiao R., Cheng C., Wang N., Cao D., Zhang T.C. The synergistic effects of cytomegalovirus IE2 and myocardin on cardiomyocyte hypertrophy. FEBS Letters 2011, 585:1082-1088.
31. Gottlieb P.D., Pierce S.A., Sims R.J., Yamagishi H., Weihe E.K., Harriss J.V., Maika S.D., Kuziel W.A., King H.L., Olson E.N., Nakagawa O., Srivastava D. Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nature Genetics 2002, 31:25-32.
32. Tan X., Rotllant J., Li H., De Deyne P., Du S.J. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:2713-2718.
33. Thompson E.C., Travers A.A. A Drosophila Smyd4 homologue is a muscle-specific transcriptional modulator involved in development. PloS One 2008, 3:e3008.
34. Hu L., Zhu Y.T., Qi C., Zhu Y.J. Identification of Smyd4 as a potential tumor suppressor gene involved in breast cancer development. Cancer Research 2009, 69:4067-4072.
35. Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006, 444:629-632.
36. Saddic L.A., West L.E., Aslanian A., Yates J.R., Rubin S.M., Gozani O., Sage J. Methylation of the retinoblastoma tumor suppressor by SMYD2. The Journal of Biological Chemistry 2010, 285:37733-37740.